跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
EVUSHELD - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
EVUSHELD
Authorized
STANDARD
EVUSHELD
astrazeneca canada inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
ce74193202ef7767
Company
astrazeneca canada inc
Type
Standard
Approval Details
Approval Id
ce74193202ef7767
Drug Approval Canada Name
EVUSHELD
Product Name
EVUSHELD
Status
Cancelled Post Market
Status Date
2024-03-27
Original Market Date
2022-04-19
Din
02526271
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Intramuscular
Schedule
Schedule D , Prescription
Ahfs
8:18.92
Atc Original
J06BD03 TIXAGEVIMAB AND CILGAVIMAB
Atc Name
j 06 bd 03
Aig Number
0263541001
Company Name
astrazeneca canada inc
Company Address
1004 Middlegate Road, Suite 5000, Mississauga, Ontario, Canada, L4Y 1M4
Active Ingredients
CILGAVIMAB
150 MG / 1.5 ML
TIXAGEVIMAB
150 MG / 1.5 ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
ce74193202ef7767
Type
Standard
Back to Health Canada Approvals